- Home
- NTIP vs CGTX Comparison
NTIP vs CGTX Comparison
Compare NTIP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- CGTX
- Stock Information
- Founded
- NTIP 1990
- CGTX 2007
- Country
- NTIP United States
- CGTX United States
- Employees
- NTIP N/A
- CGTX N/A
- Industry
- NTIP Multi-Sector Companies
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- CGTX Health Care
- Exchange
- NTIP Nasdaq
- CGTX Nasdaq
- Market Cap
- NTIP 28.6M
- CGTX 25.1M
- IPO Year
- NTIP 1998
- CGTX 2021
- Fundamental
- Price
- NTIP $1.34
- CGTX $0.57
- Analyst Decision
- NTIP
- CGTX Strong Buy
- Analyst Count
- NTIP 0
- CGTX 4
- Target Price
- NTIP N/A
- CGTX $2.83
- AVG Volume (30 Days)
- NTIP 23.9K
- CGTX 16.9M
- Earning Date
- NTIP 08-11-2025
- CGTX 08-07-2025
- Dividend Yield
- NTIP 7.46%
- CGTX N/A
- EPS Growth
- NTIP N/A
- CGTX N/A
- EPS
- NTIP N/A
- CGTX N/A
- Revenue
- NTIP $250,000.00
- CGTX N/A
- Revenue This Year
- NTIP N/A
- CGTX N/A
- Revenue Next Year
- NTIP N/A
- CGTX N/A
- P/E Ratio
- NTIP N/A
- CGTX N/A
- Revenue Growth
- NTIP N/A
- CGTX N/A
- 52 Week Low
- NTIP $1.16
- CGTX $0.22
- 52 Week High
- NTIP $1.78
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- NTIP 62.14
- CGTX 63.33
- Support Level
- NTIP $1.20
- CGTX $0.52
- Resistance Level
- NTIP $1.30
- CGTX $1.04
- Average True Range (ATR)
- NTIP 0.06
- CGTX 0.09
- MACD
- NTIP 0.01
- CGTX 0.04
- Stochastic Oscillator
- NTIP 69.23
- CGTX 40.18
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.